Vaccine Development and Regulations: Legal and Ethical Considerations

Abstract

Of the many public health interventions, vaccination stands as one of the most transformative, responsible for eradicating smallpox, curbing polio, and drastically reducing the global burden of infectious diseases. The journey from laboratory concept to licensed product, however, is a complex, costly, and highly regulated endeavor. This comprehensive review explores the multifaceted landscape of vaccine development through intersecting legal and ethical lenses. It delineates the standard multi-stage pathway for vaccine approval, from preclinical research through post-marketing surveillance, and examines the pivotal role of major regulatory agencies like the FDA and EMA in safeguarding efficacy and safety. The analysis is grounded in core ethical principles governing human subject research, including social value, informed consent, and a favorable risk-benefit ratio. Furthermore, the review investigates key legal structures, including vaccine injury compensation programs and the legal authority for mandates, while analyzing persistent tensions between intellectual property rights and equitable global access. Special ethical challenges, such as human infection studies and research in low-resource settings, are also addressed. The COVID-19 pandemic serves as a central case study, stress-testing these established frameworks. The unprecedented acceleration of development, reliance on Emergency Use Authorizations, and the stark emergence of vaccine nationalism highlighted both the remarkable agility of regulatory systems and profound vulnerabilities in global equity and public trust. The conclusion emphasizes that while the system successfully balanced urgency with prudence during the crisis, future preparedness requires strengthened regulatory harmony, robust manufacturing capacity, and more effective strategies to combat misinformation and uphold ethical commitments to global justice.